Quinlan Paul T: insider trades.
Quinlan Paul T reported 14 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 11 sales ($6.7M), across 1 company.
- Transactions
- 14
- Purchases (P)
- 0
- Sales (S)
- 11
- Companies
- 1
- Name as filed
- Quinlan Paul T
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | Officer · General Counsel | 14 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-21 | Oruka Therapeutics, Inc. | M | 10,000 | $7.8 | 39,995 | Form 4 |
| 2026-09-21 | Oruka Therapeutics, Inc. | S | 2,900 | $92.37 | 37,095 | Form 4 |
| 2026-09-21 | Oruka Therapeutics, Inc. | S | 2,667 | $95.31 | 29,995 | Form 4 |
| 2026-09-21 | Oruka Therapeutics, Inc. | S | 601 | $94.44 | 32,662 | Form 4 |
| 2026-09-21 | Oruka Therapeutics, Inc. | S | 3,832 | $93.32 | 33,263 | Form 4 |
| 2026-09-15 | Oruka Therapeutics, Inc. | S | 1,039 | $95.71 | 29,995 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 3,847 | $111.14 | 31,034 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 9,193 | $110 | 34,881 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 10,200 | $109.11 | 44,074 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 14,696 | $107.97 | 54,274 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 10,434 | $107.14 | 68,970 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | S | 3,630 | $106.05 | 79,404 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | M | 42,000 | $12.5 | 83,034 | Form 4 |
| 2026-08-14 | Oruka Therapeutics, Inc. | M | 10,000 | $7.8 | 41,034 | Form 4 |
Questions
What stock did Quinlan Paul T buy or sell?
Quinlan Paul T reported 14 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 11 sales ($6.7M), across 1 company.
Is Quinlan Paul T the same person as other filers with this name?
This page covers SEC CIK 1333277 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/quinlan-paul-t-1333277.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.